Skip to main content
    M

    Moleculin Biotech Inc (MBRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.14
    -0.73 (-9.28%)

    Market Cap: $8.02M

    Last updated: Nov 17, 2026 at 10:59 AM ET

    Moleculin Biotech Inc (MBRX) Earnings: Report Dates and Results

    Updated Nov 13, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Moleculin Biotech (MBRX) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Moleculin Biotech reported EPS of -$9.59, above the -$9.90 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    51%(19/37)
    Avg Surprise
    +5.90%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 16, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$8.70
    Range-$9.21 - -$8.40
    5 analysts
    Revenue Consensus
    N/A
    RangeN/A
    5 analysts

    Next Report

    MBRX has an expected report date of Mar 16, 2027.

    MBRX Earnings Call

    The latest MBRX earnings call transcript on file is labeled 2025Q1.

    Read the 2025Q1 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, MBRX beat 19, missed 18 and matched 1. The widest gap in the table came in the quarter ended Mar 31, 2026, when EPS landed 113.25% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReported
    Sep 30, 2026-$9.59-$9.90-$10.80 - -$6.80+3.13%BeatN/A3N/ANov 13, 2026
    Jun 30, 2026-$1.40-$1.55-$1.65 - -$1.45+9.68%BeatN/A30 up, 0 downAug 13, 2026
    Mar 31, 2026-$3.54-$1.66-$1.84 - -$1.53-113.25%MissN/A30 up, 0 downMay 14, 2026
    Dec 31, 2025$4.83-$122.27N/A+103.95%BeatN/A33 up, 0 downMar 20, 2026
    Sep 30, 2025-$0.68-$6.58-$10.00 - -$4.00+89.67%BeatN/A33 up, 0 downNov 13, 2025
    Jun 30, 2025-$12.25-$10.08N/A-21.53%MissN/AN/A0 up, 0 downAug 12, 2025
    Mar 31, 2025-$17.25-$13.87N/A-24.37%MissN/AN/A0 up, 0 downMay 13, 2025
    Dec 31, 2024-$0.56-$1.28N/A+56.60%BeatN/AN/A0 up, 0 downMar 21, 2025
    Sep 30, 2024-$71.25-$61.00-$61.00 - -$61.00-16.80%MissN/A10 up, 0 downNov 11, 2024
    Jun 30, 2024-$42.50-$62.75-$73.00 - -$52.50+32.27%BeatN/A20 up, 0 downAug 13, 2024
    Mar 31, 2024-$50.50-$88.25-$89.75 - -$86.75+42.78%BeatN/A20 up, 0 downMay 10, 2024
    Dec 31, 2023-$5.02-$3.05-$3.15 - -$2.85-64.59%MissN/A30 up, 0 downMar 22, 2024
    Sep 30, 2023-$71.25-$75.00N/A+5.00%BeatN/A30 up, 0 downNov 13, 2023
    Jun 30, 2023-$75.94-$99.37-$108.70 - -$97.45+23.58%BeatN/A30 up, 0 downAug 11, 2023
    Mar 31, 2023-$103.76-$114.37N/A+9.28%BeatN/A20 up, 0 downMay 11, 2023
    Dec 31, 2022-$0.23-$0.30-$0.35 - -$0.28+23.33%BeatN/A30 up, 0 downMar 22, 2023
    Sep 30, 2022-$112.50-$103.75N/A-8.43%MissN/A20 up, 0 downNov 10, 2022
    Jun 30, 2022-$96.82-$95.62N/A-1.25%MissN/A20 up, 0 downAug 15, 2022
    Mar 31, 2022-$90.00-$78.75-$82.46 - -$74.96-14.29%MissN/A20 up, 0 downMay 11, 2022
    Dec 31, 2021-$0.09-$0.21-$0.24 - -$0.18+57.14%BeatN/A30 up, 0 downMar 25, 2022
    Sep 30, 2021-$79.50-$77.50-$89.96 - -$59.97-2.58%MissN/A31 up, 1 downNov 11, 2021
    Jun 30, 2021-$71.40-$70.00-$82.46 - -$59.97-2.00%MissN/A3N/AAug 12, 2021
    Mar 31, 2021-$75.00-$86.25-$112.44 - -$67.47+13.04%BeatN/A3N/AMay 12, 2021
    Dec 31, 2020-$0.26-$0.58-$0.68 - -$0.51+55.17%BeatN/A3N/AMar 24, 2021
    Sep 30, 2020-$224.66-$210.00-$224.84 - -$202.36-6.98%MissN/A3N/ANov 13, 2020
    Jun 30, 2020-$189.63-$202.50N/A+6.36%BeatN/A3N/AAug 12, 2020
    Mar 31, 2020-$227.70-$225.00N/A-1.20%MissN/A2N/AMay 11, 2020
    Dec 31, 2019-$0.48-$0.66-$0.78 - -$0.60+27.27%BeatN/A3N/AMar 19, 2020
    Sep 30, 2019-$211.05-$195.00-$202.36 - -$179.87-8.23%MissN/A2N/ANov 12, 2019
    Jun 30, 2019-$192.60-$270.00N/A+28.67%BeatN/A2N/AAug 16, 2019
    Mar 31, 2019-$315.00-$202.50N/A-55.56%MissN/AN/AN/AMay 13, 2019
    Dec 31, 2018-$225.00-$225.00N/A0.00%In lineN/A2N/AFeb 21, 2019
    Sep 30, 2018-$180.00-$292.50N/A+38.46%BeatN/AN/AN/ANov 13, 2018
    Jun 30, 2018-$450.00-$315.00N/A-42.86%MissN/A1N/AAug 13, 2018
    Mar 31, 2018-$254.25-$315.00N/A+19.29%BeatN/A1N/AMay 15, 2018
    Dec 31, 2017-$0.96-$0.72N/A-33.33%MissN/AN/AN/AMar 28, 2018
    Sep 30, 2017-$0.14N/AN/AN/AN/AN/AN/AN/ANov 14, 2017
    Jun 30, 2017-$0.19N/AN/AN/AN/AN/AN/AN/AAug 14, 2017
    Mar 31, 2017-$0.72-$0.66N/A-9.09%MissN/AN/AN/AApr 3, 2017
    Sep 30, 2016-$0.12-$0.11N/A-9.09%MissN/AN/AN/ANov 21, 2016
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$25.35, after -$164.81 the year before. It was -$2.21 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$25.35N/A
    Dec 31, 2024-$164.81N/A
    Dec 31, 2023-$255.97N/A
    Dec 31, 2022-$299.55N/A
    Dec 31, 2021-$225.99N/A
    Dec 31, 2020-$642.25N/A
    Dec 31, 2019-$719.13N/A
    Dec 31, 2018-$1,109.25N/A
    Dec 31, 2017-$2.21N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2025Q1 for the period ended Mar 31, 2025, runs about 3,900 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q1Mar 31, 20253,9477
    2024Q3Sep 30, 20244,6258

    2025Q1 Earnings Call

    Opening remarks

    Jenene Thomas Investor Relations Thank you, Rod, and good morning, everyone. At this time, I'd like to remind our listeners that remarks made during this webcast may state management's intentions, beliefs, expectations, or future projections. These are forward-looking statements that involve risks and uncertainties. Forward-looking statements on this call are made pursuant to the safe harbor provisions of the Federal Securities Laws and are based on Moleculin’s current expectations and actual results could differ materially. As a result, you should not place undue reliance on any forward-looking statements. Some of the factors that could cause actual results to differ materially from these contemplated by such forward-looking statements are discussed in the periodic reports Moleculin files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on the Securities and Exchange Commission's website. We encourage you to review these documents carefully. Additionally, certain information contained in this webcast relates to or is based on studies, publications, surveys, and other data obtained from third-party sources in the company's own estimates and research. While the company believes these third-party sources to be reliable as of the date of this presentation, it does not independently verify and makes no representation as to the adequacy, fairness, accuracy, or completeness or that any independent source has verified any information obtained from third-party sources. Any data discussed regarding clinical trials and progress are considered preliminary and subject to change. Joining us on today's call from Moleculin’s leadership team are Walter Klemp, Chairman and Chief Executive Officer; Dr. John Paul Waymack, Senior Chief Medical Officer; and Jonathan Foster, Executive Vice President and Chief Financial Officer. I’d now like to turn the call over to Walter Klemp. Wally, please proceed.

    Walter Klemp Chairman and CEO Thanks, Jenene. Hello, and welcome to our first quarter earnings conference call. For most of our investors, the focus is on the Phase 3 MIRACLE trial, studying Annamycin for the treatment of relapsed and refractory acute Myeloid Leukemia. And with good reason. This trial has now officially started with the first patient already treated and more on the way. In total, we now have 38 sites selected worldwide between the US, Europe, the Middle East, and North Africa. We just announced this week that we also received complete sign off from the European Medicines Agency for all nine countries that we wanted to open in the EU. That was one of the longest lead time items for getting the EU up and running. So it was a major milestone and a real show of support from the EMA for our trial design and our objectives.

    Frequently Asked Questions About MBRX

    When is Moleculin Biotech's next earnings date?

    Moleculin Biotech's next earnings report is expected for Mar 16, 2027.

    Did MBRX beat earnings estimates last quarter?

    Yes. Moleculin Biotech reported EPS of -$9.59 for the quarter ended Sep 30, 2026, above the -$9.90 estimate, a 3.13% surprise.

    What EPS do analysts expect from MBRX next quarter?

    The consensus EPS estimate for Moleculin Biotech for the quarter ending Dec 31, 2026 is -$8.70 from 5 analysts, with estimates from -$9.21 to -$8.40.

    How often does MBRX beat earnings estimates?

    Moleculin Biotech beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +12.98%.